Indication intelligence, analysis and sector perception

Lower open expected. RegMed’s pre-open, fear sells

October 20, 2015 6:25am

Not much has changed from my perspective from last week, as I still think we will soon see a test of a bottom. The sector finds itself facing big resistance.

Tuesday’s top “10” trading indications! Subscription required: http://www.regmedinvestors.com/user/register

Make RegMed Investors your daily destination. We’ve gathered and sifted through news and share pricing data you need in one convenient spot.

DOW futures are DOWN -0.3% and NASDAQ futures are also DOWN at-0.3%

U.S. stock index futures indicated a sharply lower open on Tuesday, ahead of a deluge of third-quarter earnings as China fears continued to weigh on investor sentiment.

European equities moved lower as investor sentiment was shaken by a renewed decline in oil prices on the back of weak China data and concerns over earnings.

Asian equity markets traded mixed, with energy shares taking a hit as stubborn signs of weakness in the Chinese economy rekindled declines in oil prices.

Data docket: September housing starts and building permits figures due at 8:30 a.m. ET.

The RegMed sector closed NEUTRAL on Monday, POSITIVE on Thursday after NEGATIVE closes on Wednesday and last Tuesday.

The RegMed sector closed NEUTRAL on Monday with 20 decliners, 20 advancers and 3 flats following a NEGATIVE close on Friday with 30 decliners, 12 advancers and 1 flat following

For those who have a "fear of missing out" of the stem, cell and gene therapy RegMed sector’s upside; take a deep, deep breath , hold your nose and wait until after … the upcoming quarterly financial results <notice I didn’t say earnings release>!

Tuesday’s trading indications:

Aduro Biotech (ADRO) closed UP +$0.73 to $23.63, still undervalued – BUY;

Applied Genetic Technologies (AGTC) close DOWN-$0.14 to $12.93 on 134.1 K share volume <3 month average = 124.7 K shares> Maintaining BUY;

bluebird bio (BLUE) closed DOWN -$3.74 to $81.83, has seen better days. It’s time for a comeback – oversold – BUY;

Capricor (CAPR) closed DOWN -$0.06 to $4.51 <after Friday’s +$0.06> to $4.51 on 11.9 K share volume <3 month average = 23.3 K shares>. Be ready for a $10 to $15 M offering - Maintaining SELL;

Caladrius (CLBS) closed DOWN -$0.04 to $1.33. CLBS has seen very few good days since the new management team of Mazzo (CEO) and Vaters (CFO/President) appeared on the scene. Vaters is gone (immediately) with a “package “, is it now time to quiet the Mazzo discontent and blame the dysfunctional BOD for side-lining former CEO Robin Smith, MD. 10/1 the share price was $1.51, 9/1 was $1.70, 8/3 was $1.58, 7/1 was $1.89 and 6/1 was $2.12 – enough said to make your own decision – Maintaining SELL;

Harvard Apparatus RM (HART) closed down -$0.04 <after Friday’s -$0.04> to $0.64, oversold – BUY;

Juno therapeutics (JUNO) closed DOWN -0.92 to $49.29. 1.5 M shares traded <3 month average = 1.5 M shares>.– Maintaining SELL;

Kite Pharma (KITE) closed UP +$2.64 to $67.71 with 1.393 M shares traded <e month average = 905.5 K shares> - BUY;

Organovo (ONVO) closed DOWN -$0.01 to $3.24 after the month of October’s attrition – undervalued and oversold – BUY;

Spark Therapeutics (ONCE) closed UP +$0.78 <after Friday’s +$0.31 following Thursday’s +$1.60 post Wednesday’s +$2.86 following Tuesday’s +$0.79> to $53.59.Overbought– Maintaining SELL;

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses.

However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.